In each of the treatment arms, there are differences in overall survival (starting from 16 weeks onward) according to their classes that were identified by longitudinal global 
Figure (A) Kaplan–Meier curves for overall survival for Cetuximab plus Brivanib treatment arm. 95% confidence interval is also shown with the shaded area. (B) Kaplan–Meier curves for overall survival for Cetuximab plus placebo treatment arm. 95% confidence interval is also shown with the shaded areaFigure In addition, another sensitivity tests for OS were conducted for each of the two treatment arms with a shorter period. For this sensitivity analysis, we performed a landmark survival analysis using the first 8‐week period to generate the GMM patient classes, and then evaluated survival beyond 8 weeks, instead of our primary sensitivity analysis of using a 16‐week as cutoff (Figures 